Probiotics Efficacy on Oxidative Stress Values in Inflammatory Bowel Disease: A Randomized Double-Blinded Placebo-Controlled Pilot Study

Author(s): Andrea Ballini, Luigi Santacroce*, Stefania Cantore, Lucrezia Bottalico, Gianna Dipalma, Skender Topi, Rajiv Saini, Danila De Vito, Francesco Inchingolo.

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
(Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)

Volume 19 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Inflammatory bowel diseases (IBD), which include Crohn’s disease (CD) and ulcerative colitis (UC), are described as a chronic inflammation of the small intestine and colon, caused by a dysregulated immune response to host intestinal microbiota in genetically susceptible subjects.

Objective: The aim of this study was to compare probiotic therapy versus placebo in Oxidative Stress Values and clinical features in patients affected by IBD.

Method: Forty (40) patients previously diagnosed for IBD were recruited and randomized to receive probiotics (test group, n=20) or placebo (control group, n=20) administered for 90 days. Subjects in both the groups were assessed for overall oxidant ability (d-ROMs test) and for the antioxidant response (BAP test): data were reported at baseline, after 1 and 3 months. Additional data from anamnesis and haematological investigation were also reported during the study.

Results: d-ROM assay clearly showed that the values observed in the test group were significantly improved, leading to oxidative stress values which are not pathological. The test group showed increasing BAP values, thus confirming the overall improvements of patients ‘health following administration of probiotics.

Conclusion: Oral administration of the specific probiotics demonstrated its efficacy and safety on patients affected by IBD.

Keywords: Probiotics, Inflammatory bowel disease (IBD), gut microbiota, Immune modulation, oxidative stress, reactive oxygen species (ROS).

[1]
Anderson, A.J.M.; Click, B.; Ramos-Rivers, C.; Babichenko, D.; Koutroubakis, I.E.; Hartman, D.J.; Hashash, J.G.; Schwartz, M.; Swoger, J.; Barrie, A.M., 3rd; Dunn, M.A.; Regueiro, M.; Binion, D.G. Development of an inflammatory bowel disease research registry derived from observational electronic health record data for comprehensive clinical phenotyping. Dig. Dis. Sci., 2016, 61(11), 3236-3245.
[2]
Blumberg, R.S.; Strober, W. Prospects for research in inflammatory bowel disease. JAMA, 2001, 285(5), 643-647.
[3]
Shih, D.Q.; Targan, S.R.; McGovern, D. Recent advances in IBD pathogenesis: genetics and immunobiology. Curr. Gastroenterol. Rep., 2008, 10(6), 568-575.
[4]
Sartor, R.B. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology, 1994, 106(2), 533-539.
[5]
Sartor, R.B. Induction of mucosal immune responses by bacteria and bacterial components. Curr. Opin. Gastroenterol., 2001, 17(6), 555-561.
[6]
Satsangi, J.; Silverberg, M.S.; Vermeire, S.; Colombel, J.F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut, 2006, 55(6), 749-753.
[7]
Sartor, R.B. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol., 2006, 3(7), 390-407.
[8]
Kaser, A.; Zeissig, S.; Blumberg, R.S. Inflammatory bowel disease. Annu. Rev. Immunol., 2010, 28, 573-621.
[9]
Nemeth, Z.H.; Bogdanovski, D.A.; Barratt-Stopper, P.; Paglinco, S.R.; Antonioli, L.; Rolandelli, R.H. Crohn’s disease and ulcerative colitis show unique cytokine profiles. Cureus, 2017, 9(4), e1177.
[10]
Loh, G.; Blaut, M. Role of commensal gut bacteria in inflammatory bowel diseases. Gut Microbes, 2012, 3(6), 544-555.
[11]
Derwa, Y.; Gracie, D.J.; Hamlin, P.J.; Ford, A.C. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment. Pharmacol. Ther., 2017, 46(4), 389-400.
[12]
Aoyagi, Y.; Park, S.; Matsubara, S.; Honda, Y.; Amamoto, R.; Kushiro, A.; Miyazaki, K.; Shephard, R.J. Habitual intake of fermented milk products containing Lactobacillus casei strain Shirota and a reduced risk of hypertension in older people. Benef. Microbes, 2017, 8(1), 23-29.
[13]
Amer, M.; Nadeem, M.; Nazir, S.U.R.; Fakhar, M.; Abid, F.; Ain, Q.U.; Asif, E. Probiotics and their use in inflammatory bowel disease. Altern. Ther. Health Med., 2018, 24(3), 16-23.
[14]
Ghouri, Y.A.; Richards, D.M.; Rahimi, E.F.; Krill, J.T.; Jelinek, K.A.; DuPont, A.W. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin. Exp. Gastroenterol., 2014, 9(7), 473-487.
[15]
Tatullo, M.; Marrelli, M.; Scacco, S.; Lorusso, M.; Doria, S.; Sabatini, R.; Auteri, P.; Cagiano, R.; Inchingolo, F. Relationship between oxidative stress and “burning mouth syndrome” in female patients: A scientific hypothesis. Eur. Rev. Med. Pharmacol. Sci., 2012, 16(9), 1218-1221.
[16]
Gionchetti, P.; Rizzello, F.; Helwig, U.; Venturi, A.; Lammers, K.M.; Brigidi, P.; Vitali, B.; Poggioli, G.; Miglioli, M.; Campieri, M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology, 2003, 124(5), 1202-1209.
[17]
Ballini, A.; Santacroce, L.; Cantore, S.; Bottalico, L.; Dipalma, G.; De Vito, D.; Saini, R.; Inchingolo, F. Probiotics improve urogenital health in women. Open Access Maced. J. Med. Sci., 2018, 6(10), 1845-1850.
[18]
Sokol, H.; Pigneur, B.; Watterlot, L.; Lakhdari, O.; Bermúdez-Humarán, L.G.; Gratadoux, J.J.; Blugeon, S.; Bridonneau, C.; Furet, J.P.; Corthier, G.; Grangette, C.; Vasquez, N.; Pochart, P.; Trugnan, G.; Thomas, G.; Blottière, H.M.; Doré, J.; Marteau, P.; Seksik, P.; Langella, P. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA, 2008, 105(43), 16731-16736.
[19]
Kruis, W.; Frič, P.; Pokrotnieks, J.; Lukás, M.; Fixa, B.; Kascák, M.; Kamm, M.A.; Weismueller, J.; Beglinger, C.; Stolte, M.; Wolff, C.; Schulze, J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut, 2004, 53(11), 1617-1623.
[20]
Tatullo, M.; Gentile, S.; Paduano, F.; Santacroce, L.; Marrelli, M. Crosstalk between oral and general health status in e-smokers. Medicine (Baltimore), 2016, 95(49), e5589.
[21]
Marrelli, M.; Tatullo, M.; Dipalma, G.; Inchingolo, F. Oral infection by Staphylococcus aureus in patients affected by White Sponge Nevus: A description of two cases occurred in the same family. Int. J. Med. Sci., 2012, 9, 47-50.
[22]
Tatullo, M.; Simone, G.M.; Tarullo, F.; Irlandese, G.; Vito, D.; Marrelli, M.; Santacroce, L.; Cocco, T.; Ballini, A.; Scacco, S. Antioxidant and antitumor activity of a bioactive polyphenolic fraction isolated from the brewing process. Sci. Rep., 2016, 27(6), 36042.
[23]
Tatullo, M.; Marrelli, M.; Amantea, M.; Paduano, F.; Santacroce, L.; Gentile, S.; Scacco, S. Bioimpedance detection of oral lichen planus used as preneoplastic model. J. Cancer, 2015, 6(10), 976-983.
[24]
Marrelli, M.; Gentile, S.; Palmieri, F.; Paduano, F.; Tatullo, M. Correlation between Surgeon’s experience, surgery complexity and the alteration of stress related physiological parameters. PLoS One, 2014, 9, e112444.
[25]
Campanella, V.; Syed, J.; Santacroce, L.; Saini, R.; Ballini, A.; Inchingolo, F. Oral probiotics influence oral and respiratory tract infections in pediatric population: A randomized double-blinded placebo-controlled pilot study. Eur. Rev. Med. Pharmacol. Sci., 2018, 22(22), 8034-8041.
[26]
Dimidi, E.; Christodoulides, S.; Scott, S.M.; Whelan, K. Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation. Adv. Nutr., 2017, 8, 484-494.
[27]
Martínez-Martínez, M.I.; Calabuig-Tolsá, R.; Cauli, O. The effect of probiotics as a treatment for constipation in elderly people: A systematic review. Arch. Gerontol. Geriatr., 2017, 71, 142-149.
[28]
McFarland, L.V.; Ship, N.; Auclair, J.; Millette, M. Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: Assessing the evidence. J. Hosp. Infect., 2018, 99, 443-452.
[29]
Goldenberg, J.Z.; Yap, C.; Lytvyn, L.; Lo, C.K.; Beardsley, J.; Mertz, D.; Johnston, B.C. Probiotics for the prevention of Clostridium difficile associated diarrhea in adults and children. . Cochrane Database Syst. Rev., 2017, 12, CD006095.
[30]
Hajifaraji, M.; Jahanjou, F.; Abbasalizadeh, F.; Aghamohammadzadeh, N.; Abbasi, M.M.; Dolatkhah, N. Effect of probiotic supplements in women with gestational diabetes mellitus on inflammation and oxidative stress biomarkers: a randomized clinical trial. Asia Pac. J. Clin. Nutr., 2018, 27, 581-591.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 3
Year: 2019
Page: [373 - 381]
Pages: 9
DOI: 10.2174/1871530319666181221150352
Price: $58

Article Metrics

PDF: 32
HTML: 3